Two generations of mood stabilizers [2]

International Journal of Neuropsychopharmacology

Volumn 10, Issue 5, 2007, Pages 709-711

  Rybakowski, Janusz K ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CLOZAPINE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; OLANZAPINE; QUETIAPINE; VALPROIC ACID;

BIPOLAR DISORDER; DEPRESSION; DRUG EFFICACY; LETTER; MANIA; MENTAL DISEASE; PRIORITY JOURNAL;

ANTIMANIC AGENTS; HUMANS; MOOD DISORDERS;

EID: 34948883984     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S146114570700795X     Document Type: Letter

References (25)

1. Bauer MS, Mitchner L (2004). What is a 'mood stabilizer'? An evidence-based response. American Journal of Psychiatry 161, 3-18.
2. Bourin M, Lambert O, Guitton B (2005). Treatment of acute mania - from clinical trials to recommendations for clinical practice. Human Psychopharmacology: Clinical and Experimental 20, 15-26.
3. Bowden CL (2002). Pharmacological treatment of bipolar disorder: a review. In: Maj M, Akiskal HS, Lopez-Ibor JJ, Sartorius N (Eds.), Bipolar Disorders (pp. 191-221), Chichester, UK: John Wiley & Sons.
4. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Ashgar SA, Hompland M, Montgomery P, Earl N, Smoot TM, DeVaugh-Geiss J ; Lamicta 606 Study Group (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry 60, 392-400.
5. Brown EB, McElroy SL, Keck PE, Deldar A, Adams DH, Tohen M, Williamson DJ (2006). A 7-week, randomized, double-blind trial of olanzapine/ fluoxetine combination versus lamotrigine in the treatment of bipolar depression. Journal of Clinical Psychiatry 67, 1025-1033.
6. Calabrese JR, Keck PE, McFadden W, Minkwitz M, Ketter TA, Weisler RH, Cutler AJ, McCoy R, Wilson E, Mullen J (2005). A randomized-double-blind trial, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. American Journal of Psychiatry 162, 1351-1360.
7. Calabrese JR, Kimmel SE, Woyshville MJ, Rapport DJ, Faust CJ, Thomson PA, Meltzer HY (1996). Clozapine for treatment-refractory mania. American Journal of Psychiatry 153, 759-764.
8. Ciapparelli A, Dell'Osso L, Bandettini di Poggio A, Carmassi C, Cecconi D, Fenzi M, Chiavacci MC, Bottai M, Ramacciotti CE, Cassano GB (2003). Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder : a naturalistic 48-month follow-up study. Journal of Clinical Psychiatry 64, 451-458.
9. Cousin DA, Young AH (2007). The armamentarium of treatments for bipolar disorder: a review of the literature. International Journal of Neuropsychopharmacology 10, 411-431.
10. Gyulai L, Bowden CL, McElroy SL, Calabrese JR, Petty F, Swan AC, Chou JC, Wassef A, Risch CS, Hirschfeld RM, et al. (2003). Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 28, 1374-1382.
11. Hartigan GP (1963). The use of lithium salts in affective disorders. British Journal of Psychiatry 109, 810-814.
12. Ketter T, Calabrese JR (2002). Stabilization of mood from below versus above baseline in bipolar disorder: A new nomenclature. Journal of Clinical Psychiatry 63, 146-151.
13. Ketter TA, Wang PW, Chandler RA, Culver JL, Alarcon AM (2006). Adjunctive aripirazole in treatment-resistant bipolar depression. Annals of Clinical Psychiatry 18, 169-172.
14. Lambert PA, Borselli S, Marcou G, Bouchardy M, Cabrol G (1971). Long-term thermoregulative action of Depamide in manic-depressive psychoses [in French]. Annales Medico-Psychologiques 2, 442-447.
15. McElroy SL, Suppes T, Frye MA, Altshuler LL, Stanford K, Martens B, Leverich GS, Post RM, Keck Jr. PE (2007). Open-label aripirazole in the treatment of acute bipolar depression: a prospective pilot trial. Journal of Affective Disorders 101, 275-281.
16. Okuma T, Kishimoto A, Inue K (1973). Anti-manic and prophylactic effect of carbamazepine (Tegretol) on manic depressive psychosis. Folia Psychiatrica et Neurologica Japanica 27, 283-297.
17. Perlis RH, Welge JA, Vornik LA, Hirschfeld RM, Keck PE (2006). Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. Journal of Clinical Psychiatry 67, 509-516.
18. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT (1986). Antidepressant effect of carbamazepine. American Journal of Psychiatry 143, 29-34.
19. Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, Turkoz I, Lasser RA, Loescher A, Bouhours P, Dunbar F, Nemeroff CB (2006). Effect of risperidone augmentation in patients with treatment resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 31, 2505-2513.
20. Ravindran LN, Ravindran AV (2007). Lamotrigine in the treatment of recurrent brief depression. International Clinical Psychopharmacology 22, 121-123.
21. Rybakowski JK, Suwalska A, Chlopocka-Wozniak M (1999). Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression. Neuropsychobiology 40, 134-139.
22. Rybakowski JK, Tuszewska M (2006). Lithium or lamotrigine augmentation in treatment-resistant depression. International Journal of Neuropsychopharmacology 9 (Suppl. 1), S232.
23. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, et al. (2003). Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Archives of General Psychiatry 60, 1079-1988.
24. Vieta E, Rosa AR (2007). Evolving trends in the long-term treatment of bipolar disorder. World Journal of Biological Psychiatry 8, 4-11.
25. Zarate CA (1995). Is clozapine a mood stabilizer? Journal of Clinical Psychiatry 56, 108-112.